July 29 Management tracks: Verastem names CEO; plus Zealand, Turning Point, Arvinas and more
Verastem Inc. (NASDAQ:VSTM) named board member Brian Stuglik as CEO. In June, Robert Forrester stepped down as the cancer company's president and CEO; COO Dan Paterson succeeded Forrester as president and led the executive team while the board sought a permanent successor. Stuglik was global VP and chief marketing officer, oncology global marketing at Eli Lilly and Co. (NYSE:LLY) and has served as adviser to Verastem's commercial organization since May.
Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) said CSO and EVP Andrew Parker is leaving the GI and metabolic disease company effective Sept. 1 to take a position at another company. Zealand said a search for a successor is under way and Rie Schultz Hansen, VP of research, will serve as interim department lead...